Hemispherx BioPharma (HEB) Shares Scheduled to Reverse Split on Tuesday, June 11th

Shares of Hemispherx BioPharma, Inc (NYSEAMERICAN:HEB) are going to reverse split on the morning of Tuesday, June 11th. The 1-44 reverse split was announced on Friday, May 31st. The number of shares owned by shareholders will be adjusted after the closing bell on Monday, June 10th.

Shares of Hemispherx BioPharma stock opened at $0.10 on Friday. Hemispherx BioPharma has a 52-week low of $0.10 and a 52-week high of $0.34.

Hemispherx BioPharma (NYSEAMERICAN:HEB) last issued its earnings results on Thursday, May 16th. The specialty pharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter.

Separately, Ascendiant Capital Markets set a $1.00 target price on shares of Hemispherx BioPharma and gave the stock a “buy” rating in a report on Friday, May 17th.

TRADEMARK VIOLATION WARNING: This article was originally published by American Banking News and is the property of of American Banking News. If you are viewing this article on another publication, it was illegally copied and reposted in violation of United States and international copyright & trademark laws. The original version of this article can be read at https://www.americanbankingnews.com/2019/06/07/hemispherx-biopharma-heb-shares-scheduled-to-reverse-split-on-tuesday-june-11th.html.

About Hemispherx BioPharma

Hemispherx Biopharma, Inc, a specialty pharmaceutical company, engages in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders in the United States. The company's products include Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and Ampligen for the treatment of chronic fatigue syndrome (CFS).

Featured Story: Average Daily Trade Volume Explained

Receive News & Ratings for Hemispherx BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemispherx BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply